The Role of Interferon in the Management of BCG Refractory Nonmuscle Invasive Bladder Cancer

Table 1

Patient and tumor characteristics at the time of BCG/IFN induction.

Number of patients	44
Median age (range)	63.5	(38–92)
Male	35	79.5%
Female	7	20.5%
Median ASA	3	(2–4)
Median # of BCG inductions	1	(0–10)
<2 BCG	20	45.5%
BCG = 2	9	20.5%
>2 BCG	13	29.5%
Time to BCG failure
<6 months	20	45.5%
6–12 months	12	27.3%
12–24 months	6	13.6%
>24 months	10	22.7%
Pathology at induction
pTis	15	34.1%
pTa	16	36.4%
pT1	13	29.5%
Grade at induction
LG	5	11.4%
HG	39	88.6%
Failure of combination INF/BCG
Yes	25	56.8%
No	19	43.2%
Recurrence-free at 12 months	17	38.6%
Recurrence-free at 24 months	8	18.2%
Radical cystectomy	16	36.4%
Disease-free at 12 months	38	86.4%
Disease-free at 24 months	27	61.4%
Metastatic disease	2	4.5%
Deceased at follow-up	2	4.5%
Median follow-up	28.47	(5.3–115.3)